Abeona activates Cincinnati Children's as QTC
Analysis based on 6 articles · First reported Jul 21, 2026 · Last updated Jul 21, 2026
Live prominence charts, article sentiment distribution, and event development timeline available on the
Ergen Dashboard
The activation of a major EB center as a QTC may increase ZEVASKYN adoption and revenue for Abeona. However, the event is incremental and unlikely to significantly move the stock.
Abeona Therapeutics Inc. announced the activation of Cincinnati Children s Hospital Medical Center as the seventh Qualified Treatment Center (QTC) for the administration of ZEVASKYN, a gene therapy for recessive dystrophic epidermolysis bullosa (RDEB). This expands access to the treatment for RDEB patients in the US.
stock
Abeona expands commercial footprint for ZEVASKYN by adding a large EB center as a QTC, potentially boosting sales.
Importance 100.0
Sentiment 20.0
priv
Cincinnati Children's becomes a QTC for ZEVASKYN, offering cutting-edge gene therapy to its RDEB patients.
Importance 80.0
Sentiment 30.0
per
As Chief Commercial Officer, Vasanthavada announced the activation, highlighting collaboration with Cincinnati Children's.
Importance 30.0
Sentiment 0.0
per
Marathe, a professor at UC, expressed excitement about offering ZEVASKYN to patients at Cincinnati Children's.
Importance 20.0
Sentiment 0.0
govactor
The FDA is mentioned in safety information and as a regulatory body for reporting side effects, but not directly involved in this activation.
Importance 10.0
Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard